---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-26-000011"
form_type: "8-K/A"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-07-13T20:06:29+00:00"
generated_at: "2026-07-13T20:08:11.696207+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioMarin provides Amicus audited 2025 financials; revenue $634M, net loss $27M

## Summary
- Amicus 2025 net product sales $634.2M, up 20% YoY from $528.3M; net loss narrowed to $27.1M from $56.1M.
- Amicus had $214.0M cash, $392.7M long-term debt, and $2.77B accumulated deficit as of Dec 31, 2025.
- BioMarin acquired Amicus for $14.50/share in cash, closing April 27, 2026; this filing provides audited financials and pro forma.
- Amicus revenue concentrated: one customer accounted for 24% of 2025 net product sales.
- Pro forma condensed combined financials as of Dec 31, 2025 included in Exhibit 99.2.

## SEC filing metadata
- accession: 0001048477-26-000011
- form_type: 8-K/A
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-07-13T20:06:29+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000011/0001048477-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000011/bmrn-20260427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-26-000011
- JSON: https://secwatch.observer/filing/0001048477-26-000011.json
- Plain text: https://secwatch.observer/filing/0001048477-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.